5 Stocks Turning Heads With Double-Digit Gains

2. Viridian Therapeutics Inc. (NASDAQ:VRDN)

Viridian Therapeutics extended gains for a second day on Tuesday, soaring 33.36 percent to close at $18.75 apiece, as investor sentiment was bolstered by the looming commercialization of its eye disease treatment.

In an updated report, Viridian Therapeutics Inc. (NASDAQ:VRDN) announced readiness for the launch of veligrotug, its treatment for active and chronic thyroid eye disease (TED).

It said that it already hired a field team, including sales, to support the commercialization and supply chain infrastructure, and engaged with physicians, payers, and key opinion leaders for the treatment.

“We believe we are well-prepared and well-positioned to deliver a successful launch. With the positive topline data from REVEAL-1 and REVEAL-2, in active and chronic TED, respectively, we believe that subcutaneous elegrobart has the potential to be the simplest and most convenient treatment for TED,” Viridian Therapeutics Inc. (NASDAQ:VRDN) President and CEO Steve Mahoney said.

The company also submitted a marketing authorization application with the European Medicines Agency last January, which was accepted for review in February 2026.

Veligrotug aside, Viridian Therapeutics Inc. (NASDAQ:VRDN) widened its net loss attributable to common shareholders by 30 percent in the first quarter of the year to $92 million from $70.69 million in the same period last year.

Total revenues soared by 96 percent to $141 million from $72 million year-on-year.